Shinpoong Pharmaceutical, "Approval of Piramex UK Phase 3 Clinical Trial Plan"
[Asia Economy Reporter Lee Gwan-joo] Shinpoong Pharmaceutical announced on the 4th that it has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for a Phase 3 clinical trial plan to verify the efficacy and safety of Piramex tablets for COVID-19 patients.
Shinpoong Pharmaceutical has been conducting clinical trials to develop the antimalarial drug Piramex tablets as a treatment for COVID-19. In August of last year, it received approval from the Ministry of Food and Drug Safety for a global Phase 3 clinical trial plan.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The Phase 3 clinical trial will be conducted on approximately 1,420 patients with mild to moderate COVID-19 in Korea and the UK. Shinpoong Pharmaceutical also plans to conduct clinical trials in Poland, Colombia, Argentina, and Chile.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
